Personally found it brilliant how the authors designed this study and all the hard work behind it.
As this phase 2 study approaches patients already treated with statins (low and high dose) with or without ezetimibe and most of them on PCSK9 inhibitors (160/160 in SC group and 102/106 in IV group). Given Evinacumab's effectiveness, is it early to start to consider this agent as a promising third line just after statins and PCSK9 inhibitors? I would like to know your thoughts about including evinacumab before ezetimibe, niacin, or Mipomersen in the treatment for hyperlipidemia.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.